Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.43 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.43 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.39 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | SLC25A20 | O43772 | 3/20 | 0.37 |
| ▸ | TP53 | P04637 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.37 |
| ▸ | TBXAS1 | P24557 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9634318 | 0.84 | MEN1 (0.50) | KMT2AMEN1CYP1A2HRH1CYP2C19 | |
| SCHEMBL2201976 | 0.84 | MEN1 (0.50) | KMT2AMEN1CYP1A2HRH1CYP2C19 | |
| Perchlorate SCHEMBL9633990 | 0.82 | MEN1 (0.46) | KMT2AMEN1CYP1A2HRH1CYP2C19 | |
| Perchlorate SCHEMBL9634002 | 0.82 | MEN1 (0.46) | KMT2AMEN1CYP1A2HRH1CYP2C19 | |
| SCHEMBL17303194 | 0.80 | MEN1 (0.46) | KMT2AMEN1CYP1A2HRH1CYP2C19 | |
| SCHEMBL23531492 | 0.78 | KMT2A (0.50) | KMT2AMEN1CYP1A2HRH1CYP2C19 | |
| SCHEMBL4462543 | 0.78 | KMT2A (0.50) | KMT2AMEN1CYP1A2HRH1CYP2C19 | |
| SCHEMBL8184237 | 0.75 | MEN1 (0.47) | KMT2AMEN1CYP1A2HRH1CYP2C19 | |
| SCHEMBL5384452 | 0.73 | SMN1; SMN2 (0.47) | KMT2AMEN1CYP1A2HRH1CHRNB2 | |
| SCHEMBL28314908 | 0.73 | LMNA (0.49) | KMT2AMEN1CYP1A2CYP2C19TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2348865-B1 | BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES AND METHODS FOR THE PREPARATION AND USE THEREOF | NUCITEC SA DE CV (MX) | 2015-07-15 | — | — | EP | disclosed |
| US-8536362-B2 | β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof | NUCITEC S.A. DE C.V. (MX) | 2013-09-17 | — | — | US | disclosed |
| US-20130079308-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | NUCITEC S.A. DE C.V. (MX) | 2013-03-28 | — | — | US | disclosed |
| US-8178515-B2 | β-hydroxy-γ-aminophosphonates and methods for the preparation and use thereof | NUCITEC S.A. DE C.V. (MX) | 2012-05-15 | — | — | US | disclosed |
| EP-2348865-A2 | BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES AND METHODS FOR THE PREPARATION AND USE THEREOF | Nucitec S.A. de C.V. (MX) | 2011-08-03 | — | — | EP | disclosed |
| US-7777071-B2 | Production of carnitine conjugate intermediates | SSV THERAPEUTICS, INC. (US) | 2010-08-17 | — | — | US | disclosed |
| US-7718696-B2 | Methods of treating diabetes using carnitine conjugates as dual prodrugs | SSV THERAPEUTICS, INC. (US) | 2010-05-18 | — | — | US | disclosed |
| WO-2010041144-A2 | BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES AND METHODS FOR THE PREPARATION AND USE THEREOF | NUCITEC S.A. DE C.V. (MX) | 2010-04-15 | — | — | WO | disclosed |
| US-20100087400-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | NUCITEC S.A. DE C.V. (MX) | 2010-04-08 | — | — | US | disclosed |
| US-20090012160-A1 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof | SSV THERAPEUTICS, INC. | 2009-01-08 | — | — | US | disclosed |
| US-20080188444-A1 | Methods of treating various diseases using carnitine conjugates as dual prodrugs | SSV THERAPEUTICS, INC. (US) | 2008-08-07 | — | — | US | disclosed |
| WO-2008018877-A1 | CARNITINE CONJUGATES AS DUAL PRODRUGS, METHODS OF PRODUCTION AND USES THEREOF | SSV THERAPEUTICS, INC. (US) | 2008-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012160-A1 | Carnitine Conjugates As Dual Prodrugs, Methods Of Production And Uses Thereof | CPT1B, CRAT, CPT2 | KMT2A 1288/4885MEN1 1284/4885CYP1A2 349/4885 |
| US-20080188444-A1 | Methods of treating various diseases using carnitine conjugates as dual prodrugs | CPT1B, CRAT, SLC25A20 | KMT2A 3407/4885MEN1 2512/4885CYP1A2 675/4885 |
| US-20130079308-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | CPT1A, ACAT1, ABAT | KMT2A 1756/4885MEN1 3116/4885CYP1A2 2151/4885 |
| US-20100087400-A1 | Beta-Hydroxy-Gamma-Aminophosphonates and Methods for the Preparation and Use Thereof | CPT1A, ACAT1, ABAT | KMT2A 1756/4885MEN1 3116/4885CYP1A2 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.